Allogene Therapeutics (ALLO) Consolidated Net Income: 2019-2025
Historic Consolidated Net Income for Allogene Therapeutics (ALLO) over the last 7 years, with Sep 2025 value amounting to -$41.3 million.
- Allogene Therapeutics' Consolidated Net Income rose 36.60% to -$41.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$209.6 million, marking a year-over-year increase of 23.65%. This contributed to the annual value of -$257.6 million for FY2024, which is 21.29% up from last year.
- According to the latest figures from Q3 2025, Allogene Therapeutics' Consolidated Net Income is -$41.3 million, which was up 18.82% from -$50.9 million recorded in Q2 2025.
- Allogene Therapeutics' 5-year Consolidated Net Income high stood at $1.9 million for Q4 2021, and its period low was -$97.0 million during Q1 2023.
- In the last 3 years, Allogene Therapeutics' Consolidated Net Income had a median value of -$64.1 million in 2024 and averaged -$65.0 million.
- Per our database at Business Quant, Allogene Therapeutics' Consolidated Net Income skyrocketed by 102.76% in 2021 and then tumbled by 5,046.54% in 2022.
- Allogene Therapeutics' Consolidated Net Income (Quarterly) stood at $1.9 million in 2021, then crashed by 5,046.54% to -$93.6 million in 2022, then rose by 15.80% to -$78.8 million in 2023, then climbed by 27.02% to -$57.5 million in 2024, then spiked by 36.60% to -$41.3 million in 2025.
- Its Consolidated Net Income was -$41.3 million in Q3 2025, compared to -$50.9 million in Q2 2025 and -$59.8 million in Q1 2025.